Recommendations for the optimal introduction of novel antibiotics to treat uncomplicated gonorrhoea in the face of increasing antimicrobial resistance: a case study with zoliflodacin

Zoliflodacin, a new oral antibiotic developed in a public-private partnership, has demonstrated safety and non-inferiority to ceftriaxone plus azithromycin in a phase 3 trial. It could improve sexually transmitted infection management and address untreatable gonorrhoea. The Global Antibiotic Research & Development Partnership (GARDP) convened an expert meeting to discuss the introduction of zoliflodacin in low- and middle-income countries. Recommendations include generating evidence for zoliflodacin’s role in clinical treatment failures, additional antimicrobial resistance surveillance, and examining preferences and values among the population.